Safety and efficacy of pazopanib as a second-line treatment and beyond for soft tissue sarcomas: A real-life tertiary-center experience in the MENA region

Safety and efficacy of pazopanib as a second-line treatment and beyond for soft tissue sarcomas: A real-life tertiary-center experience in the MENA region

Introduction: Sarcomas are uncommon malignancies. No advances have been recently achieved despite multiple efforts. Pazopanib is a safe and effective tyrosine kinase inhibitor used in managing soft tissue sarcomas (STS) after chemotherapy failure. However, its use is limited in developing countries...

Full description

Bibliographic Details
Main Authors: Nour Abdul Halim, Rola El Sayed, Ibrahim A. Alameh, Jessica Khoury, Clara El Nakib, Maroun Bou Zerdan, Maya Charafeddine, Fadi Farhat, Fadi El Karak, Hazem I. Assi
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:Cancer Treatment and Research Communications
Subjects:
Soft tissue sarcoma
Pazopanib
Safety
Adverse events
Outcomes
Online Access:http://www.sciencedirect.com/science/article/pii/S2468294220301106

Internet

http://www.sciencedirect.com/science/article/pii/S2468294220301106

Similar Items